Ocugen, Inc. announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, has joined the Company?s Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company?s differentiated capabilities; and promoting access to the Company?s therapies around the world. For nearly eight years, Mr. Smith led Pfizer?s global gene therapy business, including the strategic and operational development and implementation of Pfizer?s end-to-end, enterprise-wide efforts to be an industry leader in gene therapy.

He is an accomplished biopharmaceutical executive with over thirty-five years? experience in a variety of alliance management, business development, commercial, corporate strategy, mergers and acquisitions, and research and development executive leadership roles. Mr. Smith joins Connie Collingsworth, Senator Pat Toomey, Ambassador Joseph W. Westphal, Ph.D., and Dennis Carey, Ph.D. on the BAB.

These advisors will work alongside the Executive Leadership Team to strengthen Ocugen?s network across a variety of stakeholders.